Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Venkata M Yenugonda

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Biotechniques|February 11, 2020
Cellular thermal shift analysis for interrogation of CRISPR-assisted proteomic changesNam-Gu Her, Ivan Babic, Venkata M Yenugonda, et al.
Human Antibodies|October 18, 2017
Pritumumab, the first therapeutic antibody for glioma patientsIvan Babic, Elmar Nurmemmedov, Venkata M Yenugonda, et al.
Scientific Reports|May 17, 2020
Allosteric inhibitor of β-catenin selectively targets oncogenic Wnt signaling in colon cancerAnton Cheltsov, Natsuko Nomura, Venkata M Yenugonda, et al.
Bioorganic & Medicinal Chemistry|February 5, 2015
Naturally occurring polyphenol, morin hydrate, inhibits enzymatic activity of N-methylpurine DNA glycosylase, a DNA repair enzyme with various roles in human diseaseMonica Dixon, Jordan Woodrick, Suhani Gupta, et al.
European Journal of Pharmacology|December 12, 2018
α4β2 Nicotinic receptor desensitizing compounds can decrease self-administration of cocaine and methamphetamine in ratsEdward D Levin, Amir H Rezvani, Corinne Wells, et al.
Psychopharmacology|May 31, 2017
Differential efficacies of the nicotinic α4β2 desensitizing agents in reducing nicotine self-administration in female ratsAmir H Rezvani, Susan Slade, Corinne Wells, et al.
Cancer Biology & Therapy|September 3, 2011
VMY-1-103 is a novel CDK inhibitor that disrupts chromosome organization and delays metaphase progression in medulloblastoma cellsLymor Ringer, Paul Sirajuddin, Mary Heckler, et al.
Journal of Medicinal Chemistry|September 20, 2013
Design, synthesis and discovery of picomolar selective α4β2 nicotinic acetylcholine receptor ligandsVenkata M Yenugonda, Yingxian Xiao, Edward D Levin, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Biotechniques|February 11, 2020
Cellular thermal shift analysis for interrogation of CRISPR-assisted proteomic changesNam-Gu Her, Ivan Babic, Venkata M Yenugonda, et al.
Human Antibodies|October 18, 2017
Pritumumab, the first therapeutic antibody for glioma patientsIvan Babic, Elmar Nurmemmedov, Venkata M Yenugonda, et al.
Scientific Reports|May 17, 2020
Allosteric inhibitor of β-catenin selectively targets oncogenic Wnt signaling in colon cancerAnton Cheltsov, Natsuko Nomura, Venkata M Yenugonda, et al.
Bioorganic & Medicinal Chemistry|February 5, 2015
Naturally occurring polyphenol, morin hydrate, inhibits enzymatic activity of N-methylpurine DNA glycosylase, a DNA repair enzyme with various roles in human diseaseMonica Dixon, Jordan Woodrick, Suhani Gupta, et al.
European Journal of Pharmacology|December 12, 2018
α4β2 Nicotinic receptor desensitizing compounds can decrease self-administration of cocaine and methamphetamine in ratsEdward D Levin, Amir H Rezvani, Corinne Wells, et al.
Psychopharmacology|May 31, 2017
Differential efficacies of the nicotinic α4β2 desensitizing agents in reducing nicotine self-administration in female ratsAmir H Rezvani, Susan Slade, Corinne Wells, et al.
Cancer Biology & Therapy|September 3, 2011
VMY-1-103 is a novel CDK inhibitor that disrupts chromosome organization and delays metaphase progression in medulloblastoma cellsLymor Ringer, Paul Sirajuddin, Mary Heckler, et al.
Journal of Medicinal Chemistry|September 20, 2013
Design, synthesis and discovery of picomolar selective α4β2 nicotinic acetylcholine receptor ligandsVenkata M Yenugonda, Yingxian Xiao, Edward D Levin, et al.
Pageof 1